<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753180</url>
  </required_header>
  <id_info>
    <org_study_id>CTO-201</org_study_id>
    <nct_id>NCT01753180</nct_id>
  </id_info>
  <brief_title>Total Occlusion Study in Coronary Arteries - 5</brief_title>
  <acronym>TOSCA-5</acronym>
  <official_title>A 2-stage Study to Evaluate Single Doses of MZ-004 at Different Dose Levels in Patients With Chronic Total Occlusions. Stage 1: Open Label Training Stage. Stage 2: Double-blind, Randomized, Placebo-Controlled Stage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matrizyme Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Matrizyme Pharma Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center, double blind, 2 stage, placebo-controlled, phase II study,
      evaluating acute intra-coronary injected collagenase prior to routine standard-of-care
      percutaneous revascularization procedures in subjects with chronic total coronary artery
      occlusions (CTOs).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterograde PCI success rate for patients with a target CTO</measure>
    <time_frame>Day 1 of study procedures</time_frame>
    <description>To assess the PCI success rates in CTOs that have failed a previous PCI attempt between different doses of MZ-004 and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total fluoroscopy time</measure>
    <time_frame>Day 0 and Day 1 of study procedures</time_frame>
    <description>To assess the total fluoroscopy time between patients treated with two different doses of MZ-004 and/or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total PCI procedural time</measure>
    <time_frame>Day 1 of study procedures</time_frame>
    <description>To assess the total procedural time between patients treated with two different doses of MZ-004 and/or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soft wire crossing</measure>
    <time_frame>Day 1 study procedures</time_frame>
    <description>To assess the percentage of lesions that are crossed with soft guide wires post study drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Day 0, Day 1 and Day 2 of study procedures</time_frame>
    <description>To assess the overall safety of the procedure in evaluating treatment emergent adverse events, major adverse cardiac events, radiation exposure, angiographic complications, ECGs, vital signs and clinical laboratory parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Chronic Coronary Total Occlusions</condition>
  <arm_group>
    <arm_group_label>collagenase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>collagenase</intervention_name>
    <description>Local intra-coronary administration of MZ-004 at or into the CTO</description>
    <arm_group_label>collagenase</arm_group_label>
    <other_name>MZ-004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>Local intra-coronary administration of saline at or into the CTO</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or females patients &gt; 18 years of age who has a clinically driven, planned PCI of
             the target CTO, in a major epicardial coronary artery, without planned
             revascularization of other coronary stenosis/stenoses in major epicardial segments.

          -  Target CTO must be greater than or equal to 3 calendar months prior to Screening

          -  Target CTO must meet protocol defined criteria for entry

          -  Patient is receiving a course of optimal anti-ischemic medical therapy (at least 2
             anti-anginal agents or the maximum tolerated anti-anginal therapy)

        Exclusion Criteria:

          -  Documented chest radiation exposure &gt; 4.0 Gray within 8 weeks of Day 0

          -  Target vessel is not an occluded stent, saphenous vein graft

          -  Patient had ACS &lt; 4 weeks from Screening, attributable to any coronary vessel

          -  Patient has non-healed dissection plane extending to a point adjacent to the coronary
             lumen distal to the target CTO

          -  Patient has a known or suspected target vessel perforation within 30 days of Day 0

          -  Angiographic exclusion criteria as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Buller, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto, Ontario, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hotel Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de recherche de l'Institut Universitaire de Pulmonologie et Cardiologie de Quebec</name>
      <address>
        <city>Ste. Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2012</study_first_submitted>
  <study_first_submitted_qc>December 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <last_update_submitted>July 7, 2016</last_update_submitted>
  <last_update_submitted_qc>July 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CTO</keyword>
  <keyword>PCI</keyword>
  <keyword>Angioplasty</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

